Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin for Vascular Inflammation in T2DM
NCT02077309Phase 3Terminated
- Sponsor
- RWTH Aachen University
- Start
- Aug 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin with Placebo (2 arms). Primary endpoint: Vascular inflammation of the carotid artery at 6 months. Started Aug 2014; status: terminated.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02077309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077309.